Esophageal Carcinoma Gene-Edited Cell Lines for Drug Discovery

Esophageal carcinoma (EC) is the 7th most common cancer and the 6th leading cause of cancer death worldwide, with an estimated 604,000 new cases and 544,000 deaths in 2020 (WHO GLOBOCAN). The two main histological subtypes are esophageal squamous cell carcinoma (ESCC), predominant in Asia and Africa, and esophageal adenocarcinoma (EAC), more common in Western countries. The overall 5-year survival rate is approximately 20% (NCI SEER), dropping to below 5% for metastatic disease. Key risk factors include tobacco smoking, alcohol consumption, gastroesophageal reflux disease (GERD), and obesity.

EC is an ideal model for mechanistic studies due to its distinct molecular subtypes, well-characterized genomic landscapes (TCGA, COSMIC), and availability of public datasets. Open questions include the role of tumor microenvironment, mechanisms of therapy resistance, and identification of novel therapeutic targets. Gene-edited cell models enable precise dissection of these mechanisms.

Esophageal carcinogenesis involves stepwise accumulation of genetic and epigenetic alterations. Key pathways include:

1. TP53 pathway: Loss of p53 function is an early event, leading to genomic instability.

2. Cell cycle regulation: CDKN2A (p16) inactivation and CCND1 amplification promote uncontrolled proliferation.

3. Receptor tyrosine kinase (RTK) signaling: EGFR amplification and ERBB2 (HER2) overexpression drive cell survival.

4. Wnt/beta-catenin pathway: CTNNB1 mutations and APC loss activate transcription of oncogenes.

These alterations are often modeled using CRISPR knockout or knock-in cell lines.

Data from TCGA (Nature, 2017) and COSMIC (v99).

Key deregulated signaling networks in EC include:

• • Wnt/beta-catenin pathway: CTNNB1 mutations, APC loss, leading to nuclear beta-catenin accumulation and transcription of MYC, CCND1.
• • MAPK/ERK pathway: KRAS mutations, EGFR amplification, driving proliferation and survival.
• • PI3K/AKT/mTOR pathway: PIK3CA mutations, PTEN loss, promoting cell growth and metabolism.
• • Hippo pathway: YAP1/TAZ activation, often via LATS1/2 inactivation, contributing to invasion.

These networks are frequently targeted in drug discovery using isogenic cell models.

Commonly used EC cell lines include:

Organoid cultures from patient-derived samples better recapitulate tumor heterogeneity and are used for drug sensitivity testing.

• • Patient-derived xenograft (PDX) models: Maintain tumor heterogeneity and are used for preclinical drug testing.
• • Genetically engineered mouse models (GEMMs): e.g., L2-IL1B mice for Barrett's esophagus and EAC.
• • Induced models: Carcinogen-induced (e.g., N-methyl-N-nitrosourea) models for ESCC.
• • Orthotopic models: Injection of EC cells into the esophagus for metastasis studies.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. Examples include:

• • TP53 knockout lines: Used to study loss of tumor suppression and genomic instability.
• • KRAS G12D knock-in lines: Model constitutive MAPK activation for targeted therapy testing.
• • CDKN2A knockout lines: Investigate cell cycle deregulation.
• • Reporter lines (e.g., GFP under a Wnt-responsive promoter): Monitor pathway activity in real time.

Commercially available, sequence-verified isogenic cell lines accelerate research by providing reproducible, well-characterized models, eliminating the need for in-house gene editing.

Knockout and knock-in lines validate the role of specific genes in EC progression. For example, TP53 knockout in KYSE-30 cells increases proliferation and resistance to apoptosis. KRAS G12D knock-in in TE-1 cells enhances MAPK signaling and invasion. These models are essential for target identification.

Isogenic pairs (e.g., wild-type vs. TP53 knockout) are used in high-throughput screens to identify compounds that selectively kill mutant cells. Resistance mechanisms can be studied by exposing isogenic lines to drugs (e.g., cisplatin) and analyzing acquired mutations via sequencing.

CRISPR synthetic lethality screens identify genes that become essential in the context of specific mutations (e.g., TP53 loss). For example, targeting WEE1 or CHK1 in TP53-mutant EC cells leads to selective cell death, providing a therapeutic strategy. Such screens rely on isogenic cell models.